Using Plasma Proteomics to Predict Amyotrophic Lateral Sclerosis (ALS) @checkrare
Using Plasma Proteomics to Predict Amyotrophic Lateral Sclerosis (ALS)  @checkrare
Uploaded October 2026 | Updated November 2026, 4 hours ago
Michael Benatar, MD, PhD, Department of Neurology and ALS Center, University of Miami Miller School of Medicine, discusses the use of plasma proteomics in predicting clinical manifestations of amyotrophic lateral sclerosis (ALS).

For the full interview, visit checkrare.com/plasma-proteomics-may-predict-disease-manifestations-in-als
Using Plasma Proteomics to Predict Amyotrophic Lateral Sclerosis (ALS)FDA Approves Gazyva for Idiopathic Nephrotic Syndrome, Offering a New Treatment OptionGaretosmab Demonstrates Sustained Efficacy in Adults With Fibrodysplasia Ossificans ProgressivaApproval of Imaavy (Nipocalimab) and its Impact on Patients With Warm Autoimmune Hemolytic AnemiaGazyva Treatment: Steroid-Free Remission in Idiopathic Nephrotic SyndromeTherapies for MCT8 Deficiency and Nephrotic Syndrome Get FDA ApprovalUltragenyx Sells PRV for $210MCh 4: Treatment Gaps in C3GMaking Travel Accessible: SMAshing My Limits Partners With Becoming rentABLEResults From the Voice of PBC Patient SurveyUltragenyx Gets $203M in Second Priority Review Voucher This MonthPatient Perspective: Diagnosis and Treatment Journey With ROS1-Positive Non-Small Cell Lung Cancer
CheckRare |

Using Plasma Proteomics to Predict Amyotrophic Lateral Sclerosis (ALS)

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER